Six The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV from the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which includes bosentan, sitaxentan and ambrisentan are oral therapies licensed to be used in PAH. As no oral agent has revealed superiority there remains discussion concerning https://tracleer80134.livebloggs.com/32096721/a-simple-key-for-tracleer-unveiled